JP2020527027A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527027A5 JP2020527027A5 JP2019567333A JP2019567333A JP2020527027A5 JP 2020527027 A5 JP2020527027 A5 JP 2020527027A5 JP 2019567333 A JP2019567333 A JP 2019567333A JP 2019567333 A JP2019567333 A JP 2019567333A JP 2020527027 A5 JP2020527027 A5 JP 2020527027A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cell lymphoma
- trbc1
- cell
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 15
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 15
- 208000000389 T-cell leukemia Diseases 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 9
- 101000662909 Homo sapiens T cell receptor beta constant 1 Proteins 0.000 claims description 9
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 9
- 102100037272 T cell receptor beta constant 1 Human genes 0.000 claims description 9
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 9
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- 206010066957 hepatosplenic T-cell lymphoma Diseases 0.000 claims description 6
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims description 6
- 150000007523 nucleic acids Chemical group 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 239000000611 antibody drug conjugate Substances 0.000 claims description 4
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims description 3
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 3
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 3
- 208000037902 enteropathy Diseases 0.000 claims description 3
- 208000028774 intestinal disease Diseases 0.000 claims description 3
- 201000005962 mycosis fungoides Diseases 0.000 claims description 3
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000033371 Extranodal NK/T-cell lymphoma, nasal type Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022130014A JP2022159473A (ja) | 2017-06-09 | 2022-08-17 | 抗ｔｒｂｃ１抗原結合ドメイン |
| JP2025081388A JP2025107475A (ja) | 2017-06-09 | 2025-05-14 | 抗ｔｒｂｃ１抗原結合ドメイン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1709203.2 | 2017-06-09 | ||
| GBGB1709203.2A GB201709203D0 (en) | 2017-06-09 | 2017-06-09 | Antigen-binding domain |
| PCT/GB2018/051570 WO2018224844A1 (en) | 2017-06-09 | 2018-06-08 | Anti trbc1 antigen binding domains |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130014A Division JP2022159473A (ja) | 2017-06-09 | 2022-08-17 | 抗ｔｒｂｃ１抗原結合ドメイン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020527027A JP2020527027A (ja) | 2020-09-03 |
| JP2020527027A5 true JP2020527027A5 (enExample) | 2021-04-30 |
| JP7177794B2 JP7177794B2 (ja) | 2022-11-24 |
Family
ID=59358238
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567333A Active JP7177794B2 (ja) | 2017-06-09 | 2018-06-08 | 抗ｔｒｂｃ１抗原結合ドメイン |
| JP2022130014A Withdrawn JP2022159473A (ja) | 2017-06-09 | 2022-08-17 | 抗ｔｒｂｃ１抗原結合ドメイン |
| JP2025081388A Pending JP2025107475A (ja) | 2017-06-09 | 2025-05-14 | 抗ｔｒｂｃ１抗原結合ドメイン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130014A Withdrawn JP2022159473A (ja) | 2017-06-09 | 2022-08-17 | 抗ｔｒｂｃ１抗原結合ドメイン |
| JP2025081388A Pending JP2025107475A (ja) | 2017-06-09 | 2025-05-14 | 抗ｔｒｂｃ１抗原結合ドメイン |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11440961B2 (enExample) |
| EP (1) | EP3635006A1 (enExample) |
| JP (3) | JP7177794B2 (enExample) |
| KR (1) | KR102743539B1 (enExample) |
| CN (2) | CN110741018B (enExample) |
| AU (1) | AU2018282038B2 (enExample) |
| BR (1) | BR112019025990A2 (enExample) |
| CA (1) | CA3065006A1 (enExample) |
| CL (1) | CL2019003536A1 (enExample) |
| CO (1) | CO2019013614A2 (enExample) |
| CU (1) | CU24663B1 (enExample) |
| GB (1) | GB201709203D0 (enExample) |
| IL (1) | IL270731B2 (enExample) |
| MX (1) | MX2019013387A (enExample) |
| MY (1) | MY205039A (enExample) |
| PE (1) | PE20191717A1 (enExample) |
| PH (1) | PH12019502785A1 (enExample) |
| WO (1) | WO2018224844A1 (enExample) |
| ZA (1) | ZA201907524B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| US11982672B2 (en) | 2014-03-05 | 2024-05-14 | Autolus Limited | Methods |
| GB201709203D0 (en) * | 2017-06-09 | 2017-07-26 | Autolus Ltd | Antigen-binding domain |
| GB201800298D0 (en) | 2018-01-09 | 2018-02-21 | Autolus Ltd | Method |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| GB201812650D0 (en) | 2018-08-03 | 2018-09-19 | Autolus Ltd | Molecular assessment of TRBC usage |
| GB201817172D0 (en) | 2018-10-22 | 2018-12-05 | Autolus Ltd | Antibody |
| GB201817822D0 (en) | 2018-10-31 | 2018-12-19 | Autolus Ltd | Binding domain |
| WO2020172605A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| JP7710373B2 (ja) * | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| CN115135672A (zh) * | 2019-12-20 | 2022-09-30 | 波赛达治疗公司 | 抗muc1组合物和使用方法 |
| CA3166629A1 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| TW202144418A (zh) * | 2020-03-13 | 2021-12-01 | 美商健生生物科技公司 | 唾液酸結合Ｉｇ樣凝集素結合的材料及方法 |
| EP4121518A4 (en) * | 2020-03-16 | 2024-06-19 | Marengo Therapeutics, Inc. | MODIFIED CELL COMPOSITIONS AND METHODS OF USE |
| GB202004263D0 (en) * | 2020-03-24 | 2020-05-06 | Autolus Ltd | Antibody conjugate |
| GB202005216D0 (en) | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| JP7784811B2 (ja) | 2020-04-22 | 2025-12-12 | 住友化学株式会社 | 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法 |
| KR20230028242A (ko) * | 2020-04-24 | 2023-02-28 | 마렝고 테라퓨틱스, 인크. | T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도 |
| JP2022008152A (ja) | 2020-06-25 | 2022-01-13 | 住友化学株式会社 | 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法 |
| JP7758480B2 (ja) | 2020-07-01 | 2025-10-22 | 住友化学株式会社 | 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法 |
| CN111909277A (zh) * | 2020-08-13 | 2020-11-10 | 上海市第一人民医院 | 一种靶向trbc1的人源化嵌合抗原受体、t细胞及用途 |
| EP4204458A4 (en) * | 2020-08-26 | 2024-10-09 | Marengo Therapeutics, Inc. | METHODS FOR DETECTION OF TRBC1 OR TRBC2 |
| JP7790991B2 (ja) | 2021-02-12 | 2025-12-23 | 住友化学株式会社 | 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法 |
| AU2022222679A1 (en) * | 2021-02-17 | 2023-09-07 | The Johns Hopkins University | Methods and materials for treating clonal t cell expansions |
| JP2022164585A (ja) | 2021-04-15 | 2022-10-27 | 住友化学株式会社 | 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法 |
| JP2022164583A (ja) | 2021-04-15 | 2022-10-27 | 住友化学株式会社 | 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法 |
| US20230004084A1 (en) | 2021-05-06 | 2023-01-05 | Sumitomo Chemical Company, Limited | Salt, acid generator, resist composition and method for producing resist pattern |
| CN114181971A (zh) * | 2021-11-22 | 2022-03-15 | 东莞市麦亘生物科技有限公司 | 一种靶向trbc1 car-t细胞的制备方法与应用 |
| CN114853893A (zh) * | 2022-02-23 | 2022-08-05 | 南京蓝盾生物科技有限公司 | 一种靶向gpc3嵌合抗原受体t细胞及其应用 |
| TW202430550A (zh) * | 2022-10-18 | 2024-08-01 | 日商明治製菓藥業股份有限公司 | Ｔ細胞性腫瘤之治療劑 |
| WO2024256824A1 (en) | 2023-06-14 | 2024-12-19 | Autolus Limited | Chimeric antigen receptors directed against trbc1 and trbc2 |
| WO2025007013A2 (en) * | 2023-06-28 | 2025-01-02 | The Johns Hopkins University | Trbc targeting antibody-drug conjugates |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| CN119912570A (zh) * | 2024-12-30 | 2025-05-02 | 武汉科技大学 | 一种抗trbc1纳米抗体及其制备方法与应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006506954A (ja) | 2002-04-29 | 2006-03-02 | ゲンパト７７ ファーマコジェネティクス エージー | Ｔｃｒ及びｔｉｒｃ７に結合する新規な抗体、並びに治療及び診断におけるその使用 |
| RU2355703C2 (ru) | 2002-10-09 | 2009-05-20 | Медиджен Лимитед | Одноцепочечные рекомбинантные т-клеточные рецепторы |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US8518405B2 (en) * | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| DK2893004T3 (en) * | 2012-09-04 | 2019-02-04 | Cellectis | MULTI-CHAIN CHEMICAL ANTIGEN RECEPTOR AND APPLICATIONS THEREOF |
| PL3241561T3 (pl) * | 2014-03-05 | 2025-09-01 | Autolus Limited | Skoniugowane przeciwciało lub bi-specyficzny środek angażujący komórki T, które selektywnie wiążą region stały 1 TCR beta (TRBC1) lub TRBC2 |
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| JP2017514471A (ja) * | 2014-04-23 | 2017-06-08 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 |
| CA2956482A1 (en) * | 2014-07-31 | 2016-02-04 | Cellectis | Ror1 specific multi-chain chimeric antigen receptor |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| GB201501936D0 (en) | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
| GB201503133D0 (en) | 2015-02-24 | 2015-04-08 | Ucl Business Plc And Syncona Partners Llp | Chimeric protein |
| GB201709203D0 (en) * | 2017-06-09 | 2017-07-26 | Autolus Ltd | Antigen-binding domain |
| GB201800298D0 (en) | 2018-01-09 | 2018-02-21 | Autolus Ltd | Method |
-
2017
- 2017-06-09 GB GBGB1709203.2A patent/GB201709203D0/en not_active Ceased
-
2018
- 2018-06-08 KR KR1020207000285A patent/KR102743539B1/ko active Active
- 2018-06-08 CN CN201880037850.5A patent/CN110741018B/zh active Active
- 2018-06-08 IL IL270731A patent/IL270731B2/en unknown
- 2018-06-08 MY MYPI2019007209A patent/MY205039A/en unknown
- 2018-06-08 EP EP18733324.0A patent/EP3635006A1/en active Pending
- 2018-06-08 WO PCT/GB2018/051570 patent/WO2018224844A1/en not_active Ceased
- 2018-06-08 CN CN202410491767.2A patent/CN118480126A/zh active Pending
- 2018-06-08 PE PE2019002428A patent/PE20191717A1/es unknown
- 2018-06-08 MX MX2019013387A patent/MX2019013387A/es unknown
- 2018-06-08 AU AU2018282038A patent/AU2018282038B2/en active Active
- 2018-06-08 CA CA3065006A patent/CA3065006A1/en active Pending
- 2018-06-08 BR BR112019025990-2A patent/BR112019025990A2/pt unknown
- 2018-06-08 CU CU2019000099A patent/CU24663B1/es unknown
- 2018-06-08 US US16/620,370 patent/US11440961B2/en active Active
- 2018-06-08 JP JP2019567333A patent/JP7177794B2/ja active Active
-
2019
- 2019-11-13 ZA ZA2019/07524A patent/ZA201907524B/en unknown
- 2019-12-02 CO CONC2019/0013614A patent/CO2019013614A2/es unknown
- 2019-12-04 CL CL2019003536A patent/CL2019003536A1/es unknown
- 2019-12-10 PH PH12019502785A patent/PH12019502785A1/en unknown
-
2021
- 2021-10-12 US US17/499,687 patent/US11434293B2/en active Active
-
2022
- 2022-08-03 US US17/817,271 patent/US20230053849A1/en active Pending
- 2022-08-17 JP JP2022130014A patent/JP2022159473A/ja not_active Withdrawn
-
2025
- 2025-05-14 JP JP2025081388A patent/JP2025107475A/ja active Pending